Trendlines Group Portfolio Company IBI Ag Achieves Breakthrough with AI-Driven Bioinsecticide Platform

Key Highlights

• IBI Ag, a portfolio company of The Trendlines Group Ltd., successfully completed proof-of-concept (POC) for its AI-driven de novo protein design platform for bioinsecticides.
• The new platform leverages proprietary biological data and advanced AI to design and validate novel proteins targeting key agricultural pests.
• Newly designed proteins have shown efficacy in insect bioassays, demonstrating effectiveness against major agricultural pests while aiming to minimize impact on beneficial insects and the environment.
• This is believed to be the first ever de novo protein design platform specifically for bioinsecticides, marking a paradigm shift in sustainable crop protection.

Details for Investors

Investors should take note of a significant milestone reported by The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY) regarding its portfolio company, IBI Ag. The company has achieved a successful proof-of-concept for its artificial intelligence-driven platform dedicated to the de novo design of novel bioinsecticide proteins.

Traditionally, bioinsecticides rely on naturally occurring proteins, but IBI Ag’s platform utilizes advanced AI and proprietary datasets to computationally design proteins tailored to target specific pests. This approach enables the creation of bioinsecticides that not only selectively and effectively target harmful insects, but also seek to minimize collateral impact on beneficial species and the environment.

The proof-of-concept was robust, with the designed proteins being validated in insect bioassays—experiments that confirmed the proteins’ efficacy against agricultural pests. This validation is crucial for both regulatory pathways and future commercialization.

The CEO of IBI Ag, Arnon Heyman, emphasized the novelty of this achievement, stating, “To the best of our knowledge, this is the first ever de novo protein design platform for bioinsecticides. It is designed to leverage the company’s proprietary IP for targets in insect control. This allows us to discover and validate new proteins based on vast amounts of data which we believe is a game-changer in the industry.”

Importantly for shareholders, the platform’s capacity for de novo design allows IBI Ag to address pest challenges that were previously inaccessible using conventional approaches. This opens up new commercial opportunities, enabling the company to pursue markets that require highly specific pest control solutions. Additionally, the platform is expected to deliver products with improved commercial attributes such as higher gross margins, longer shelf life, greater stability, and resiliency.

Potential Price-Sensitive and Shareholder-Relevant Information

• First-in-industry AI-driven de novo protein design for bioinsecticides: If successfully scaled, this technological lead could position IBI Ag and, by extension, The Trendlines Group, as major innovators in sustainable crop protection—a sector with strong regulatory and market tailwinds.
• Substantial pipeline expansion and new market entry potential: The ability to target previously untreatable pests means Trendlines’ exposure to new and potentially lucrative market segments.
• Commercial advantages: Higher gross margins, improved product shelf life, and product resiliency could significantly enhance profitability and market competitiveness.
• Sustainability and ESG alignment: The platform is directly aligned with increasing regulatory and consumer demands for sustainable and environmentally-friendly agricultural solutions, enhancing Trendlines’ ESG profile—a key consideration for institutional investors.
• Validation of Trendlines’ investment approach: This milestone underscores the strength and depth of Trendlines’ portfolio in translating early-stage innovation into potentially high-impact, market-ready solutions.

Management Commentary

“Completing this proof of concept is a major milestone for IBI Ag. This advancement not only demonstrates our commitment to sustainability but also supports farmers in achieving higher yields without compromising the health of ecosystems.”
— Arnon Heyman, CEO of IBI Ag

“IBI Ag’s achievement underscores the strength, depth and significant market potential of the Trendlines portfolio.”
— Haim Brosh, CEO of Trendlines

“We are proud to support companies that turn innovation into real-world impact aligned with industry needs for sustainability and global food security.”
— Nitza Kardish, PhD, Trendlines EVP Head of Agrifood

About The Trendlines Group Ltd.

The Trendlines Group invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term shareholder value.

Investor Contact Information

Israel:
Shira Zimmerman, The Trendlines Group
Email: [email protected]
Tel: +972.72.260.7000

Singapore:
Kamal Samuel, Financial PR
Email: [email protected]
Rishika Tiwari, Financial PR
Email: [email protected]
Tel: +65.6438.2990

Disclaimer

This article is for informational purposes only and should not be construed as investment advice. The information is based on a company press release and has not been independently verified. The Singapore Exchange Securities Trading Limited assumes no responsibility for the contents of this article. Investors should consult their own professional advisors before making any investment decisions.

View Trendlines Historical chart here